Find Clinical Trial

Home » Find Clinical Trials » A Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in PreviouslyTreated Japanese Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

A Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in PreviouslyTreated Japanese Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

← Back

Study Phase	Phase 2

Therapeutic Area	Cancers

Indication	Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S.)

Active substance/ Medical device	Ivosidenib

Active Substance Code	S95031

Protocol Code	CL2-95031-008

NCT Code	NCT06081829

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.